Oyster Point Pharma is a US-based biopharmaceutical company that develops and commercializes pharmaceutical therapies for ophthalmic diseases. Its product candidate, TYRVAYA, is a nicotinic acetylcholine receptor agonist for treating dry eye disease and neurotrophic keratopathy. The company was founded in 2015 and is headquartered in Princeton, New Jersey.